Navigation Links
Entegrion Announces Organizational Changes to Support Advanced Product Development
Date:6/19/2013

Research Triangle Park, NC (PRWEB) June 19, 2013

North Carolina-based life sciences company Entegrion, Inc., announced organizational changes to advance development of its technologies.

Entegrion’s Executive Chairman John B. Mowell said, “To support the advanced development of our product candidates Entegrion’s Board of Directors has made changes to the Company’s management structure and engaged industry leaders as key advisors.”

The Company announced that Michael Galiger will serve as Vice President of Operations with primary responsibility for development of Entegrion’s plasma product Resusix, as well as supporting the continued advancement of the Company’s other technologies. “Mike’s technical background, intensive work with the development of Entegrion’s products, and his success in attracting a solid product development team, including Stacy Hammonds as Director of Clinical Operations, and Taegen Sullivan, Product Development Engineer, have made a substantial contribution to Entegrion’s success,” Mowell continued.

Entegrion also announced the formation of a clinical advisory Board initially comprised of Paul Ness, MD, Director of Transfusion Medicine at Johns Hopkins; Professor Peter Rhee, MD, Chief of Trauma, Critical Care, Burns and Emergency Surgery, University of Arizona; Edward Scott, MD, President of Key Biologics; and Philip C. Spinella, MD, Director, Pediatric Critical Care Translational Research Program, Washington University, St. Louis.

“We are immensely proud to be associated with these world-class leaders in transfusion and trauma medicine. Drs. Rhee and Spinella both came out of the Armed Forces and served in Iraq. They will bring a unique ‘user perspective’ to our technologies. Dr. Scott has decades of experience with the supply of blood and blood derivatives, and Dr. Ness is an expert in transfusion medicine. Their guidance will be invaluable as our biologic and medical device technologies move into advanced development,” Mowell said.

Entegrion also announced that Richard Martin will serve as Executive Vice President with responsibility for Entegrion’s overall day-to-day business operations reporting to the Executive Chairman, and will assist in the areas of strategic corporate planning and development. Susan Reyer, the Company’s Controller for the past five years, now serves as Vice President, Chief Financial Officer, with responsibility for the Company’s financial and administrative matters.

Joseph DaCorta will continue in his role as Chief Technology Officer, with responsibility for managing Entegrion’s government relations and exploring new opportunities to utilize the Company’s technologies. Arthur Bode continues to serve as Vice President, Chief Science Officer in charge of scientific research and project support.

Mowell stated, “We are fortunate that each of the senior members of our management team have been integral to the company’s operations for a number of years, positioning Entegrion well for continued success.”

Over the past three years, Entegrion has announced Department of Defense contract awards totaling more than $50 million for the development of resuscitation and coagulation technologies that have important healthcare applications for US Armed Forces.

About Entegrion
Entegrion, Inc. is a life sciences product development company that is focused on improving the safety and availability of the world’s blood supply. Based in North Carolina’s Research Triangle Park, Entegrion offers patented technologies designed to overcome limitations in storage, safety, and availability of blood-derived products while preserving their functionality. Many of Entegrion’s advances in biologics are based on close collaborations with leading medical research institutions. Visit http://www.entegrion.com for more information.

Read the full story at http://www.prweb.com/releases/2013EntegrionLeadership/06Updates/prweb10848250.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Bird-B-Gone Inc.® Announces Launch of Pond Defender™
2. Viewpoints TV Announces June Air Dates for Phoenix, AZ
3. Arem Wellness Announces a Recipe Contest
4. CoachingWebsites (Websites for Coaches) Announces Their Partnership With Active Intelligence, LLC
5. MinuteHound Announces How Cloud Computing Technology Boosts Savings
6. Internationally Acclaimed Breast Augmentation Expert Announces the Launch of His New Website
7. hCGTreatments / Diet Doc hCG Diets & Weight Loss Plans Announces Improved hCG Diet Plans, Fast Weight Loss Now Thought to Decrease Risk of Heart Disease
8. Vet Supply Source Announces Sweepstakes Contest Winner
9. VegasHotelEscapes Announces Special Hotel Packages For Dash Berlin At The Lavo
10. Tarrant Plastic Surgery Announces Summer Makeover Special
11. Rottenstein Law Group LLP Announces New Tylenol Lawsuit Center
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2017)... Palm Beach, FL (PRWEB) , ... April 21, 2017 , ... The staff at Palm ... , will be taking part in the 2017 London Marathon. Set to take place on ... of charitable organizations. This year, Dr. Schwartz will run as part of team EMPOWER, raising ...
(Date:4/21/2017)... ... April 21, 2017 , ... Evoke Therapy Programs , ... kicked off its 4th annual Forum for Innovative Treatment Solutions (FITS), which runs ... Therapy for Mental Health and Addiction.” , FITS’ 2017 keynote presenters will ...
(Date:4/21/2017)... ... April 21, 2017 , ... Dudnyk has announced the launch of its new ... the full potential of specialty and orphan brands can only be achieved when the ... “The Unifying Effect is at the heart of a true partnership between our agency ...
(Date:4/21/2017)... ... 2017 , ... The VIA Agency , a full-service ... Theravent, Inc. , the makers of a revolutionary new device clinically proven to ... working to expand distribution in anticipation of a national launch. VIA will be ...
(Date:4/21/2017)... ... April 21, 2017 , ... ... campaign, AWARE: A Week of Addiction and Recovery Education, from April 24 to ... and preventing substance use disorders. , The mission of AWARE is to ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)...  Cogentix Medical, Inc. (NASDAQ: CGNT), a global ... Uro/Gyn and Gynecology markets with innovative and proprietary ... the Company as Senior Vice President, Marketing & ... Keswani will report directly to Darin Hammers ... is delighted that Ash has joined the Cogentix ...
(Date:4/20/2017)... Mass. , April 20, 2017  RXi ... developing innovative therapeutics that address significant unmet medical ... data from the Company,s consumer product development program, ... at the Society for Investigative Dermatology (SID) 76 ... to advance and promote the sciences relevant to ...
(Date:4/20/2017)... -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today ... C virus (HCV) infected patients with genotype 1, ... (Child-Pugh A) achieved sustained virologic response at 12 ... pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). These high SVR ... of G/P treatment without ribavirin. Patients with specific ...
Breaking Medicine Technology: